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Current evidence indicates the existence of at least  10 allelic forms of HLA- 
DR  alloantigens  (1).  More  recently, several  other  B  cell  antigens  have  been 
defined: DC, MB, MT, TE, LB, DS, and SB (2). Some of these specificities exist 
as separate molecular entities distinct from DR antigens. Others may be public 
determinants located on  DR  antigens;  some may be  identical.  These data,  in 
conjunction with the appearance of as many as 9 or 10 spots on two-dimensional 
gel electrophoreses of DR antigen preparations, support the existence of multiple 
DR-like antigens (2). 
The basic structure of conventional DR antigens is well established and has 
been extensively reviewed (2-4). On the basis of N-terminal sequence analyses, 
DR antigens are thought to represent the human analogue ofmurine I-E antigens 
(5).  These antigens consist of a  biomolecular complex of non-disulfide-linked 
sialoglycoproteins [(p29),(p34)l] (2). The nearly complete amino acid sequences 
of both heavy a and light/3 chains for DR2 have been reported (6, 7) and several 
laboratories have reported analyses of cDNA clones for both  heavy and  light 
chain DR genes (2, 3, 8, 9). 
Structural analysis of non-DR,  class  II antigens is less extensive. In general, 
the structures are similar to  DR  but  differences in  molecular weights and  in 
isoelectric points  (pI)  have  been  reported  (2).  Partial  N-terminal  amino acid 
sequences for these antigens have also been reported (10,  11) and recently the 
DNA sequence of a  cDNA clone coding for the heavy chain of DC1  has been 
reported (12). The DC 1 antigen is thought to represent the human counterpart 
of the murine I-A antigen (2,  10,  13). 
We have recently described a  polymorphic, HLA-D/DR-Iike, ~ human B cell- 
* To  whom  correspondence should be addressed at  the Hematology Service, Clinical  Center, 
National Institutes of Health, Bethesda, MD 20205. 
* Fellow of the Arthritis Foundation. 
Descriptive terminology for human B cell alloantigens is presently in a state of flux. The term 
HLA-D/DR is used to signify the human analog of murine H-21  and is used interchangeably with 
class 11 or la-like antigens. 
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specific antigen detected by monoclonal antibody (MAb)  2 33.1.3 It was postulated 
that the 33.1  antigen is a non-DR but Ia-like molecule encoded or regulated by 
a  gene(s) linked to those responsible for the expression of the human analogue 
(DC) of the murine I-A region. We now present further evidence to support this 
assignment from analyses of DR homozygous typing cells and DR "null" mutant 
cell lines, and from partial N-terminal-radiolabeled amino acid sequence analyses. 
These  results  suggest  that  the  33.1  antigen  is  closely  related  to  previously 
described human I-A antigens (DS and DC). 
Materials and Methods 
MAb.  MAb  33.1  is an  IgG1 ~ as previously described (14);  IVG1, an  IgGl  K (poly- 
morphic ~-HLA-DR) and I-2, an IgG,,, ~ (monomorphic a-HLA-DR) have been previously 
described (15,  16).  An  anti-HLA-A,B,C  framework  MAb  (61D2)  was  also  used  (15). 
Ascites fluid (AF) for each MAb was used to isolate an IgG fraction from DEAL cellulose. 
This IgG fraction was coupled to cyanogen bromide (CNBr) Sepharose 4B (Pharmacia, 
Inc., Piscataway, NJ)  at  ~2  mg/ml wet-packed beads (17).  For some experiments, the 
DEAL IgG fraction of MAb 33.1  AF was further fractionated on protein A-Sepharose 
(Pharmacia, Inc.) to obtain an IgG~ fraction (18) that was then coupled to CNBr Sepharose. 
Cell Lines.  TRAL (HLA-A3, B7, D/DR2), JMIT (D/DR1), KCAR (HLA-A2, B7, D/ 
DR2), ESU (D/DR1), PYOD (DR4,w6), WALK (D/DR4), TDOH (D9, DRw6,7), KSTE 
(D/DR5),  PBUR  (DR7),  and  PY  (D/DR4,w6)  were  obtained  from  the  Naval  Tissue 
Typing Bank, Bethesda, MD. KCAR is consanguineous. HOM-2 (HLA-A3, B27, D/DR1), 
HERROD/HOM-1  (HLA-A3, B27, D/DR2; consanguineous), I-6W3, (DR3), 1-10W10, 
I-7WB7, and I-9W4 (DR4); DHI (DR5, consanguineous), I-3W6 (DRw6), I-2W9 (DR2), 
1-13W7  (DR7), IBW9 (DR7, MB3; consanguineous), and SHA (HLA-2, 17, D7,1, DR7, 
MB3; consanguineous) were obtained from J. Sachs, London, England.  K4B (DR  1,3), 
22B, WFB,  H9B (DR2,3);  F1B (DR4,w6),  C1B (DR3,7,  MB2,3), E1B2 (DR2,5),  Q1B 
(DR1,7), and S11B (DR2,3) were obtained from W. Biddison, NCI. AMDB (DR2), SBVL 
and LOST (DR3), PARO (DR2,w9), PAJA (DR2,3), WOCH (DRw6,7), PAAF (OR2,w9), 
AMSO (DR7,w9), LOJA (DR3,4), and LOT1 (DR2,4) were obtained from M. Robinson, 
NIAID. The cell lines WIL-2 (HLA-A1, A2, B5, B17, DR7, 8), SWEIG (DR5/5), and SB 
(HLA-A1,  A2,  B12,  B17,  DR2,w6)  were obtained from D.  Howell, Duke  University, 
Durham,  NC.  All  of the  above cell lines are  Epstein-Barr virus (EBV)-transformed B 
lymphoblastoid cell lines (BLCL) and were maintained in 90% RPMI 1640, 10% fetal calf 
serum supplemented with glutamine and antibiotics. SeD is an EBV-transformed BLCL 
derived from spleen cells of an individual with chronic lymphocytic leukemia (CLL); it 
was obtained from S.  M.  Fu, The Rockefeller University, NY (19).  Three EBV-trans- 
formed sublines of RAMOS and two EBV-transformed sublines of BJAB were obtained 
from G. Klein, Uppsala, Sweden. RAMOS and BJAB are EBV genome-negative Burkitt 
cell lines (20). The cell line GM3107 (PGF) used by Goyert et al. (11) was obtained from 
the Human Mutant Cell Repository in Camden, NJ and is a D/DR2 homozygous BLCL. 
Mutant Cell Lines: HLA Mutants.  The DR null mutants used in this study were derived 
by two stages of mutagenesis: 3' irradiation and appropriate immunoselection with anti- 
body and complement.  4 Parental BLCL 721  was irradiated and selected with anti-HLA- 
B8 to yield mutant 721.45.1 from which one haplotype had been physically deleted (21). 
The remaining haplotype of 721.45.1 includes HLA-A2, B5, DC 1/MB 1, and SB2. BLCL 
2 Abbreviations  used in this paper:  AF, ascites fluid; BLCL, B lymphoblastoid  cell line; BSA, bovine 
serum albumin; CLL, chronic lymphocytic leukemia; CNBr, cyanogen bromide; EBV, Epstein-Barr 
virus; ELISA, enzyme-linked immunosorbent assay; FCM, flow cytometry; MAb, monoclonal anti- 
body; PBS, phosphate-buffered saline; PHA, phytohemagglutinin; Phe, phenylalanine; SDS-PAGE, 
sodium dodecyl sulfate-polyacrylamide  gel electrophoresis; sIF, surface immunofluorescence. 
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721.45.1 was irradiated and immunoselected with MAb L243 (a-HLA-DR monomorphic; 
22,  23) to isolate several DR null  mutant cell  lines (49).  They are designated DR null 
because they neither bind MAb L243 in an enzyme-linked immunosorbent assay (ELISA) 
nor are they killed by anti-HLA-DR-typing alloantisera in complement-dependent cyto- 
toxicity tests (24). Some of the DR null mutant cell lines continued to express DC1/MB1, 
while other did not. All of the DR null mutant cell lines express SB2 (22). 
Surface Immunofluorescence (slF) and Flow Cytometry (FCM).  The methods used have been 
described in a  previous paper? Briefly, cells were washed in phosphate-buffered saline 
(PBS)  with  0.02%  sodium  azide.  For  both  microscopic sIF and  FCM,  106  cells  were 
incubated  with  saturating amounts  of MAb,  washed,  and stained  with  fluorescein- or 
rhodamine-conjugated goat anti-mouse antiserum (IgG fraction; Cappel Laboratories Inc., 
Cochranville, PA). A Leitz Ortholux epifluorescence microscope (E. Leitz, Inc., Rockleigh, 
N  J) or a fluorescence-activated cell sorter (FACS II; B-D FACS Systems, Sunnyvale, CA) 
was used to observe and record sIF, In a separate series of experiments, MAb 61D2, 33.1, 
and  I-2  were  conjugated  with  fluorescein  or  rhodamine  using  conventional  methods. 
These reagents were used to evaluate capping of the respective antigens recognized by 
these reagents.  For co-capping experiments, BLCL cells  were stained sequentially with 
fluoresceinated MAb I-2 and rhodamine-conjugated MAb 33.1. After the cells had been 
incubated at 37°C for various amounts of time (10-60 min), the second MAb was added 
in PBS containing 0.02% sodium azide. Papain-treated cells were prepared by the method 
of Schwartz and Nathenson (25) and examined for sIF after 5-60 min of digestion. The 
anti-HLA framework MAb was used as a positive control. Tunicamycin-treated cells (26) 
were also examined. 
ELISA.  Immunoassay plates (flat-bottomed) 96-weU, NUNC 4-39454) were pretreated 
by a 30-min incubation at room temperature (RT) with 50 #1 of poly-L-lysine solution (10 
ug/ml in PBS;  Sigma Chemical Co., St.  Louis, MO). Cells harvested during exponential 
growth  (105  per  well  in  100  #1)  were  centrifuged  and  fixed  with  100  #i  of  0.5% 
glutaraldehyde for 15 min at RT. The glutaraldehyde was removed by two washes with 
PBS and further inactivated by incubation  for 30  rain at RT with  100 #l  of 100  mM 
glycine in PBS containing 0.1% bovine serum albumin (BSA). Antibody binding to fixed 
cells was evaluated using a  beta-galactosidase-conjngated F(ab')z sheep anti-mouse IgG 
(heavy and light) (9502SA; Bethesda Research Laboratories, Rockville, MD). The ELISA 
was conducted as previously described (27) except that p-nitrophenyl-/~-gaiactopyranoside 
was  used as  the substrate.  The reaction  was quenched  with  0.5  M  calcium carbonate 
solution and read on an automated ELISA reader (Flow Laboratories, McLean, VA) at 
405 nm wavelength. The binding of MAb 33.1  was titrated on the HLA-hapioid mutant 
cell line 721.45.1  with HLA genotype A2-B5-DR1-MBI-Dwl-SB2. Half-maximum bind- 
ing was observed at an antibody concentration of ~  1:8,000 dilution of AF.  Results are 
given as the mean OD ×  1,000 for duplicate samples. 
Isolation of  Radiolabeled 33.1 Antigen.  Various BLCL cells (1-5 ×  108) were radiolabeled 
with  [3H]phenylalanine  ([3H]Phe)  (1-5  mCi)  using  methods previously described  (28). 
Cells  were  radiolabeled  for  8-16  h  in  mid-log phase;  at  the  termination  of labeling, 
viability was 285%. Incubation periods for the incorporation of the [s~S]methionine were 
8-10  h.  In some experiments, tunicamycin (8-10 #g/ml) was added  to the cells being 
radiolabeled (26). Radiolabeled cells (40-60% incorporation) were lysed in 0.25% Nonidet 
P-40, 10 mM Tris, 0.15 M NaCI, pH 8.0. The detergent lysate was centrifuged at 100,000 
g for 60 min and applied directly to an immunoadsorbent column containing either MAb 
33.1,  IVG1, or I-2. Specifically bound material was eluted with 0.5% diethylamine and 
neutralized with 2 M Tris, pH 8.0. The eluted material was concentrated and dialyzed by 
ultrafiltration  using a  PM10  membrane (Amicon Corp.,  Danvers,  MA).  Samples were 
analyzed on 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
according  to  the  method  of  Laemmli  (29).  Analytical  slab  gels  were  fixed  in  50% 
trichloroacetic acid, dried, and autoradiographed using Kodak X-Omat AR film with an 
intensifying screen  (30).  Samples for protein  sequence  analysis were  isolated by using 
preparative SDS-PAGE with  a  10-15%  acrylamide gradient  in  20-cm tubes.  The gels 
were extruded, frozen at -20°C, and sliced in 2-mm sections. The sections were incubated MARTI  ET  AL.  1927 
overnight at 40-50°C in 0.001% SDS to elute the peptide chains. After counting samples 
of these  fractions  to  determine  the  positions  of  the  chains,  fractions  were  pooled, 
centrifuged to remove acrylamide debris, and lyophilized to dryness. Dried samples were 
taken up in 0.5-1.0 ml of 0.001% SDS for amino acid sequence analysis. 
Amino Acid Sequence Determination.  The method  used  has been previously described 
(28).  Briefly,  the  sequences  of the  isolated  a  and  3  chains  were  determined  on  an 
automated  sequencer  (model  890C;  Beckman  Instruments,  Inc.,  Fullerton,  CA).  Butyl 
chloride extracts were collected and evaporated to dryness under N2;  scintillation  fluid 
was added  (Biofluor;  New  England  Nuclear,  Boston,  MA) and  radioactivity  measured 
(Beckman LC 9000; Beckman Instruments, Inc.). 
Sequential Immunoadsorption  Affinity Column Chromatography.  A  [3H]Phe-labeled HOM- 
2 lysate was sequentially passed through 33.1-Sepharose and IVG 1-Sepharose immunoad- 
sorption  columns.  The lysates were cycled overnight in the cold on each column. The 
columns were washed first with starting buffer and then with  2% sodium deoxycholate 
until the radioactivity decreased to background level. The specifically bound material was 
eluted with 3 M NH4SCN and immediately desalted on Sephadex G-25 that was connected 
directly to the immunoadsorbent column, a and/3 chains were isolated as described above. 
Results 
slF.  Panel studies were undertaken  to evaluate the association between  33.1 
and DR antigens. A  representative survey of cells tested by FCM and microscopic 
slF with MAb 33.1  is summarized  in Table  I. EBV BLCL derived from individ- 
uals homozygous for DR  1,  2, 4,  5, and w6 are positive while most DR3/3  and 
DR7/7  cells  are  unreactive.  DRw8,  DRw9,  or  DRwl0  homozygous cells  were 
not available to us, but cells heterozygous for DRw8 (7/w8) or DRw9 (7/w9) are 
positive.  Microscopic slF consistently revealed that ->95% of the cells of a  given 
TABLE  I 
DR Specificity and MAb 33. I Reactivity 
DR  MAb 33,1 
Cell designation  Specificity  Reactivity 
HOM-2, ESU, JMIT  1,1  Positive 
721.45.1 *  1  Positive 
TRAL, KCAR, HERROD, I-2w9  2,2  Positive 
I-6W3, SBVL, LOST  3,3  Negative 
721.127*  3  Negative 
1-10W10, WALK, I-7WB7, I-9W4  4,4  Positive 
KSTE, DHI, SWEIG  5,5  Positive 
I-3W6  w6,w6  Positive 
I-13W7, LAZ, PBUR, 3824, RAMOS*  7,7  Negative 
SeD  ~;  7,7  Positive 
SHA  0  7,7  Positive 
AMSO  7,w9  Positive 
C 1B  3,7  Positive 
M 1781  5,7  Negative 
WIL-2  7,w8  Positive 
* 721.45.1 and 721.127 are deletion mutants with only one MHC haplotype remaining; 
see text for details. 
* The RAMOS and SeD cell lines do not react with any monospecific anti-DR alloanti- 
sera except anti-DR7  alloantisera.  In addition,  SeD  is reactive  with  MB2 and -3 
antisera  (A. Johnson, private communication). 
0 SHA is an EBV BLCL derived from an HLA-D recombinant individual (47). 
! M 17B is EBV BLCL derived from an individual with an HLA-A3 variant (48). 1928  A  NOVEL  HLA-D/DR-LIKE  ANTIGEN 
positive cell line expressed the 33.1 antigen. This finding was confirmed by FCM 
(data  not shown).  The  presence of 33.1  on  EBV-transformed  cells may be an 
autologous marker of B cell activation as previously suggested (14). 
In  an  attempt  to demonstrate  the  nonidentity  of the  33.1  antigen  with  DR 
antigens,  dual  fluorescence studies  were undertaken.  Dual  fluorescent experi- 
ments using MAb 33.1  and  MAb I-2 (a-HLA-DR,  monomorphic)  showed that 
induction of surface patching by MAb 33.1 did not affect the surface distribution 
of DR as detected by MAb I-2. Also, there was no decrease in sIF of MAb 33.1 
on papain-treated  or tunicamycin-treated  cells.  Papain-treated  cells did show a 
rapid  and  almost  complete  loss  of antigens  recognized  by the  a-HLA  class  I 
framework MAb. 
Genetic Analysis  of HLA Deletion Mutant Cell Lines.  A  panel of HLA deletion 
mutant  cell  lines  has  been  prepared  that  allows  the  genetic  discrimination  of 
three subregions (DR, MB/DC, and SB) within  the HLA region, each of which 
controls the expression of distinct Ia-like molecules. 4 Analysis of the binding of 
MAb 33.1  to this panel of mutant cell lines (by ELISA) was used to determine 
which subregion controls the expression of the Ia-like molecule to which MAb 
33.1  binds.  The  binding  of MAb  33.1  on  the  hemizygous  parental  cell  line 
721.45.1  and on  13 DR null mutant cell lines was analyzed over an appropriate 
range of MAb concentration  (Fig.  1). Of the  13 DR null lines tested, 9 retained 
expression of the DC1  molecule. All 13 of the DR null lines retain expression of 
the SB marker. 4 MAb 33.1  binds to the hemizygous parent and to all nine of the 
lines that  retained  expression of the DC1  molecule.  However, it does not bind 
measurably to any of the four lines that have lost expression of the DC1 marker. 
Tbese data demonstrate that expression of the 33.1 antigen "cosegregates" with 
the DC1  molecule in these mutants,  but its expression  is clearly distinguishable 
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FIGURE  1.  Binding of the 33.1  antibody to HLA deletion mutant cell lines. Binding of MAb 
33.1  to cell lines was measured by an ELISA on a panel of HLA deletion lymphoblastoid cell 
lines including three categories of mutants: (a) line 45.1  (HLA mutant), which retained only 
one HLA haplotype, including DR1, DC1, SB2 (- • .); (b) nine (DR null) sublines derived from 
45.1, which had lost DR 1 expression but retained DC1  and SB2 (- -  -); and (c) four sublines 
of 45.1  which had lost DRI  and DC1, but retained SB2 (--). MARTI  ET  AL.  1929 
from that of DR (which is lacking in all the DR null cell lines) and of SB (which 
is retained in all the DR null cell lines). 
Comparative SDS-PAGE A~alysis of the 33.1 Antigen.  To demonstrate that the 
33. I  antigen is different from HLA-DR antigens, HOM-2  lysates were sequen- 
tially  passed  through  33.1-Sepharose  and  IVG1-Sepharose  immunoadsorption 
columns.  The  sequentially  immunoadsorbed  33.1  antigen  and  IVG1  antigen 
differ according to their electrophoretic mobility of SDS-PAGE (Fig. 2). There 
are  multiple bands on  the  slab  gel  for  both  ~  and  fl chains of these antigens, 
presumably due to differential glycosylation or heterogeneity of molecules within 
the Ia family. Under reducing conditions, the 33.1  antigen has a  34,000 mol wt 
(34  K) a  chain that is substantially smaller than the a  chain (35 K and 37 K) of 
the IVG1  (DR) antigen. The two reduced 3  chain bands (27.5  K and 29 K) of 
33.1  have  molecular  weights  similar  to  the  3  chain  of IVG1  antigen.  Under 
nonreducing conditions,  the apparent  molecular weight of the  33.1  antigen  oe 
chain (32.5  K) is still less than that of the IVG1  antigen a  chain (34  K  and  36 
K); the apparent molecular weight of the nonreduced 3 chain of the 33.1 antigen 
(22  K)  is  less  than  the  major  band  of  IVG1  antigen  3  chain  (24  K).  These 
observations  not  only demonstrate  the  nonidentity of s-DR  (IVG1)  and  33.1 
chains, but also suggest the nonidentity of their respective/3 chains. 
The 33.1  antigen could be isolated from cell lysates bound to lectin columns, 
indicating the presence of a carbohydrate side chain. A decrease in the apparent 
molecular weight of the  33.1  antigen  after exposure of cells to tunicamycin is 
also consistent with this interpretation (Fig. 3). Although tunicamycin treatment 
only partially  inhibited glycosylation in this experiment, the nonglycosylated /3 
chain (21  K) is 3,000  tool wt smaller than the glycosylated 3 chain (Fig. 3). Due 
to the interference of glycosylated/3 chain, the nonglycosylated 0t chain is not 
well identified. 
Amino  Acid  Sequence Determination  of 33.1  a  (or  Heavy) and  3  (or  Ligh  0 
Chains.  The ascending portion of the 0~ chain peak and the descending portion 
of the/3 chain peak eluted from SDS-PAGE gels were pooled separately so as to 
FrGURE 2.  SDS-PAGE of[3H]Phe-labeled HLA-DR and [3H]Phe  33.1  antigens from HOM- 
2  cells purified by sequential immunoadsorbent column chromatography. A and D contain 
molecular weight standards. B and C contain reduced 33.1 antigen and DR antigens, respec- 
tively. E and F contain nonreduced 33.1 antigen and DR antigen, respectively. 1930  A  NOVEL  HLA-D/DR-LIKE ANTIGEN 
FIGURE 3.  SDS-PAGE of 33.1 antigen from tunicamycin-treated  KCAR cells (B) and normal 
KCAR cells (C). 
TABLE  II 
Comparison  of,V-Terminal Ami~m Acids in Class H a  Chains 
Position 
Cell  D/DR  Antigen 
12  18  22  24  26  29  32 
HOM-2  D/DR1  F  F  F  F  F  IVG1 (DR1) 
HOM-2  D/DR 1  F  F  33.1 
TRAL  D/DR2  F  F  33.1 
KCAR  D/DR2  F  F  33.1 
Priess*  DR4/4, SB3,4  F  F  F  F  SB-3 
Priess*  DR4/4, SB3,4  F  F  F  F  DR4 
BLCL*  D/DR2  F  F  F  F  DR2 
GM3107(PGF) j  D/DR2  DS2 
GM3107(PGF)  D/DR2  F  F  33.1 
JY!  DR4,w6  F  F  DC 1 
Raft*  DR3,w6  F  F  F  F  F  Ia-like 
* Hurley et al. (40). 
* Yang et al. (6). 
0 Govert et al. (l 1). 
!  AuiTray et al. (12), Bono and Strominger (10). 
'  Larhammer et al. (8). 
avoid  cross-contamination  of the  chains.  The  [3H]Phe-labeled  DR  and  33.1  a 
chains are  shown  in  Table  II along with  previously published  data  for a  chains 
of class II, D/DR-like alloantigens.  Among the 32 N-terminal positions analyzed, 
the 33.1  o~ chain from all three cell lines examined contains Phe residues only at 
position  18 and 29; a  similar pattern  has been reported (10) for the DC 1 ot chain. 
This  sequence  is readily  distinguished  from the  DR and  SB a  chain  sequences, 
which  contain  Phe  at  positions  12,  22,  24,  26,  and  32.  Goyert et  al.  (11)  have 
isolated  and  sequenced a  non-DR, but  Ia-like antigen  (DS2)  from a  D/DR2  cell 
line  and  have  designated  it  as  a  human  equivalent  of the  murine  I-A antigen. 
The  lack  of Phe  in  the  first  20  N-terminal  positions  differentiates  it  from  the 
33.1  a  chain.  We  obtained  the  same  DR2  cell  line,  GM3107  (PGF),  used  by 
Goyert et  al.  (11),  and  HLA-DR  typing was consistent  with  its  DR2  specificity. 
Also,  its  reaction  with  MAb  33.1  confirmed  its  human  origin.  As  can  be  seen 
(Table  II),  its  33.1  a  chain  sequence  is the  same as that  obtained  for the  other MARTI  ET  AL. 
TABLE  III 
Comparison of N-Terminal Amino Acids in Class II 3 Chains 
1931 
Cell  D/DR 
Position 
7  9  11  13  17  18 
Antigen 
HOM-2 
HOM-2 
TRAL 
KCAR 
Priess* 
Priess* 
BLCL* 
GM 3107(PGF)  j 
GM3107(PGF) 
LB  ! 
Raji  ~ 
D/DRI  F 
D/DRI  F  F 
D/DR2  F  F  F 
D/DR2  F  F  F 
DR4/4, SB3,4 
DR4/4, SB3,4  F 
D/DR2  F 
D/DR2  F  F 
D/DR2  F  F  F 
DR w6,w6 
DR3,w6  F  F 
F  F 
F 
F 
F 
IVG1 (DR1) 
33.1 
33.1 
33.1 
SB-3 
DR4 
DR2 
DS2 
33.1 
DC1 
Ia-like 
* Hurley et al. (40). 
*  Kratzin et al. (7). 
Goyert et al. (11). 
I  Bono and Strominger (12), 
Wiman et al, (9), Larhammer et al. (8). 
three cell lines studies. 
Analyses of the  N-terminal  28  residues  of [sH]Phe-labeled  DR and  33.1  /3 
chains are shown in Table III. The SB-3/3 chain sequence is very different from 
the 33.1/3 chain sequences obtained. This observation further supports previous 
results s that  the 33.1  antigen  is not SB. Derived from a  single cell line (HOM- 
2), the/3 chain  sequences for DR and  33.1  are distinctly different.  The  33.1  /3 
chain sequence from two separate DR2/2 cell lines (TRAL, KCAR) differs from 
the DR2/2 /3 chain sequence as determined by Kratzin  et al. (7) at positions 9, 
11, and  18. The DC 1 /3 chain is reported to be blocked at the N-terminus (10). 
The  33.1  and  DS/3 chain sequences are very closely related but the sequences 
obtained from D/DR2 cell lines differ at position 9. In addition, the 33.1/3 chain 
sequence obtained from GM3107 (PGF) is identical to the sequences found for 
two other D/DR2 BLCL, i.e.,  KCAR and TRAL. However, it should be noted 
that  the  DS/3 chain  sequence for GM3107  (D/DR2) is identical  to the  33.1  /3 
chain sequence for HOM-2 (D/DR1). 
Discussion 
This report describes the isolation and initial characterization of a new human 
B  lymphocyte-specific antigen,  33.1.  This antigen  can be detected and isolated 
using murine  MAb 33.1,  prepared  by immunization  of mice with a  human  D/ 
DR2 lymphoblastoid cell line.  The data presented in this report show that 33.1 
is  a  human  class  II  major  histocompatibility  complex  (MHC)  antigen  that  is 
clearly not DR. The antigen is homologous to the previously described non-DR 
antigens DS and DC but can be distinguished from them by both structural and 
cellular distribution data (11,  13). 
The  class II nature  of 33.1  was suggested by earlier  studies  3 indicating  that 
the antigen  is present  on  B  cells and  not on  T  cells,  and  SDS-PAGE analysis 1932  A  NOVEL  HLA-D/DR-LIKE  ANTIGEN 
demonstrated  that  33.1  consists  of two  noncovalently  associated  chains  with 
molecular  weights  appropriate  for  class  II  antigens.  In  addition,  intrachain 
disulfide bonds were shown to be present. The present report shows, in addition, 
that 33.1  is a glycoprotein and that it exhibits, on the cell surface, the expected 
resistance to papain digestion. 
Two kinds of evidence suggest that the 33.1  antigen maps to or is genetically 
controlled in the D/DR region of the MHC. First, the antigen is absent on most 
DR3 and DR7 homozygous cell lines. This association was confirmed by ELISA. 
MAb 33.1  binds to BLCL 721  and to 721.45.1  from which the DR3 expression 
has  been  deleted  but  fails  to  bind  significantly  to  mutants  that  retain  DR3 
(721.127) after loss of the DR1  haplotype (Table I). Second, the expression of 
the  33.1  antigen  was  lost  only  on  those  DR  null  mutants  lacking  DC1/MB1 
reactivity. This is strong evidence that genes controlling the expression of DC1 
and 33.1  are linked closely enough to be deleted together.  Attempts are being 
made to isolate mutants that lose expression of either DC 1 or 33.1 but not both. 
Numerous lines of evidence show that  33.1  is not DR. MAb directed against 
DR  can  be  used  to  exhaustively  deplete  cell  lysates  of DR  antigens  without 
affecting the  level of 33.1  and  vice versa.  Capping of 33.1  on the cell surface 
does not lead to capping of DR antigens.  When DR and 33.1  are isolated from 
the  same  cell  line,  the  ~  and  /3  chains  of 33.1  can  be  shown  to  be  of lower 
molecular weight than  the corresponding DR chains.  Although some investiga- 
tors (5) have been  unable to detect  molecular weight differences between DR 
and  non-DR but  Ia-like antigens,  this does not appear  to be the case for  33.1 
and  DR.  Furthermore,  partial  N-terminal  sequence analysis conclusively dem- 
onstrates that major differences exist between 33.1 and DR in both chains. 
While 33.1  is clearly a non-DR, class II antigen, the relationship between 33.1 
and previously described non-DR antigens  is more difficult to determine  (31- 
40). Two distinct non-DR loci, SB and DC, are universally recognized (2,  10,  13, 
31,  40).  It  is  possible  to  distinguish  33.1  and  SB  quite  easily  by amino  acid 
sequence analysis and  by mapping  using a  panel  of DR null  mutant  cell lines. 
However, the structural  and  mutant  cell pane] data demonstrate  that  33.1  is a 
member of the DC family of molecules. 
The  DC family appears to include the human  homologues of the mouse I-A 
antigens.  The diversity that  exists within  this family is currently an active area 
of research. Studies at the nucleic acid level sugest a level of complexity sufficient 
to encompass a  number of related antigens  (41).  Evidence has been presented 
that there are at least two DC-like ~ chain genes (10, 41, 42) and several DC-like 
/3 chain genes (8, 41-43). It is unknown whether all of these genes are expressed 
at the protein level and whether any restrictions exist with respect to association 
between the gene products of the various a  and/3 chains either within the DC 
family or more widely among other class II antigens. 
The  two members of the  DC  family that  have  been  described  in  sufficient 
detail  to  permit  comparisons  with  33.1  are  DC1  and  DS.  While  there  are 
similarities  among  the  three  antigens,  there are  differences both  in  structural 
features  and  in  the  pattern  of expression.  The  limited  protein  sequence data 
available reveal some differences. The amino acid N-terminal  sequences of the 
33.1  and  DC1  o~ chains are indistinguishable,  with  Phe at positions  18 and  29. MARTI  ET  AL.  1933 
Although inconclusive, no Phe was found at residue  18 in the DS ot chain.  The 
/3 chain  of DC1  has been reported  to be blocked (10).  The  two 33.1  /3 chains 
from DR2/DW2 homozygous cell lines contain Phe at positions 7, 9,  11, and  17, 
but DS from a  DR2/DW2 cell line (GM3107) lacks the Phe at position 9  even 
though  Phe  is  present  at  position  7  and  11.  Furthermore,  the  33.1  13 chain 
isolated from GM3107 (PGF) does contain Phe at position 9, further suggesting 
that 33.1  and DS may not be identical when isolated from the same cell line. In 
a  similar  investigation  using  five  radiolabeled  amino  acids  and  murine  MAb 
IVD12  (anti-MB3),  Giles et  al.  (44)  have  noted  structural  variations  between 
IVD12 and  DS/3 chains.  They have tentatively attributed  this variation  to the 
existence of polymorphic alleles.  The  33.1  /3 chain  sequences do exhibit poly- 
morphism  at Phe positions.  The existence of a  DR null,  DC null,  33.1-positive 
mutant cell line would provide direct evidence that 33.1 and DC1 are different. 
In addition  to the amino  acid sequence differences between 33.1  and other 
human I-A antigens (DS, DC), the patterns of tissue distribution vary considerably 
for these antigens.  MAb 33.1  recognizes a B cell-specific antigen.  Expression of 
this antigen is restricted to BLCL, activated and neoplastic B cells (CLL lympho- 
cytes included), and unstimulated  B lymphocytes of blood, tonsil, lymph nodes, 
and  spleen?  In  contrast,  Gonwa et al.  (45),  using a  rabbit  anti-marmoset  I-A 
antiserum,  have shown that the majority of human blood monocytes express the 
DS antigen.  There  is a  striking  similarity  in  the tissue distribution  of the  33.1 
and  IVD12  antigens  on  a  small  population  of blood monocytes and  on  CLL 
lymphocytes (44). Shackelford et al. (13) have used MAb Genox 3.53 to isolate 
and characterize DC1. As detected by Genox 3.53, DC1 is present on BLCL and 
peripheral  blood B cells but is absent on blood T  iymphocytes and Molt 4 cells. 
Lung macrophages were stated to be positive (46). Genox 3.53 binds to phyto- 
hemagglutin  (PHA)-stimulated peripheral  T  cells (personal communication,  D. 
Shackelford), but MAb 33.1  does not. 
While 33.1, DC, DS, and IVD12 are very similar with respect to their a  chain 
sequences, they do not appear to be identical in/3 chain sequences. More extensive 
protein sequence data or transfection experiments using cloned a  and 13 chains 
genes will be required to relate the various class II antigens to the various a  and 
/3 chain  genes that  have been detected and partially characterized.  Direct com- 
parison of the various antigens,  using the same set of reagents and the same cell 
lines  for  study,  may  ultimately  be  necessary  to  resolve  these  questions.  The 
distinctive tissue distributions, particularly the absence of 33.1 on monocytes and 
PHA blasts and, in contrast, the presence of DC1 on monocytes and PHA blasts, 
suggest that these similar antigens may be very different in their functional roles 
in cell-cell recognition (45). The availability of reagents such as MAb 33.1 should, 
in conjunction with studies at the nucleic acid level, facilitate the functional and 
molecular  dissection  of the  human  Ia  antigen  system  as  it  relates  to  immune 
regulation and associated disease states. 
Summary 
The polymorphic human  B cell-specific antigen,  33.1, detected by a  murine 
monoclonal  antibody,  was  compared  by  genetics  and  structural  analysis  with 
known human  Ia antigens  from a  panel of DR homozygous Epstein-Barr virus- 1934  A  NOVEL  HLA-D/DR-LIKE  ANTIGEN 
transformed B  lymphoblastoid cell lines.  Cells  homozygous for DR  1,  2,  4,  5, 
and  w6  were  positive,  while  cells  that  are  DR3,3  or  DR7,7  usually  failed  to 
express this antigen.  Mutant  DR null,  DC/MB-positive cells were 33.1  positive 
while  DR null,  DC/MB-negative  cells failed to express this antigen,  suggesting 
the segregation of 33.1  with the DC antigen.  Sodium dodecyl sulfate-polyacryl- 
amide  gel  electrophoresis analysis  revealed  that  33.1  a  and  3  chains  were  of 
lower molecular weights than the DR ot and 3 chains isolated from the same cell 
line.  Partial  N-terminal amino acid sequence analyses were carried out for the 
heavy and light chains of the 33.1  antigen radiolabeled with [SH]phenylalanine. 
The  results  of  these  analyses,  in  conjunction  with  previous  data  on  tissue 
distribution, indicate that the 33.1 antigen is a non-DR but Ia-like antigen closely 
related to the previously defined I-A homologues, DC and DS. 
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